Value of altered methylation patterns of genes RANBP3, LCP2 and GRAP2 in cfDNA in breast cancer diagnosis

Altered Methylation in cfDNA for Breast Cancer Diagnosis

  • Qin Hu
  • Yu Mao
  • Haomiao Lan
  • Yi Wei
  • Yuehua Chen
  • Qiang Ye
  • Hongying Che Zigong First People's Hospital
DOI: https://doi.org/10.5937/jomb0-47507
Keywords: methylation pattern, RANBP3, LCP2 GRAP2, cfDNA, breast cancer

Abstract


Background: The purpose of this study was to investigate the potential of plasma cfDNA methylation patterns in reflecting tumor methylation changes, focusing on three candidate sites, cg02469161, cg11528914, and cg20131654. These sites were selected for verification, with a particular emphasis on their association with breast cancer.

Methods: We conducted a comprehensive analysis of 850k whole-methylation sequencing data to identify potential markers for breast cancer detection. Subsequently, we examined the methylation status of genes RANBP3, LCP2, and GRAP2, where the aforementioned sites are located, using cancer and cancer-adjacent tissues from 17 breast cancer patients. We also assessed the methylation patterns in different molecular subtypes and pathological grades of breast cancer. Additionally, we compared the methylation levels of these genes in plasma cfDNA to their performance in tissues.

Results: Our analysis revealed that RANBP3, LCP2, and GRAP2 genes exhibited significant methylation differences between cancer and cancer-adjacent tissues. In breast cancer, these genes displayed diagnostic efficiencies of 91.0%, 90.6%, and 92.2%, respectively. Notably, RANBP3 showed a tendency towards lower methylation in HR+ breast cancer, and LCP2 methylation was correlated with tumor malignancy. Importantly, the methylation levels of these three genes in plasma cfDNA closely mirrored their tissue counterparts, with diagnostic efficiencies of 83.3%, 83.9%, and 77.6% for RANBP3, LCP2, and GRAP2, respectively.

Conclusions: Our findings suggest that RANBP3, LCP2, and GRAP2 genes, located at the identified methylation sites, can serve as valuable blood molecular markers for the auxiliary diagnosis of breast cancer. This research provides a foundation for further exploration of gene methylation pattern changes in cfDNA for the detection of breast cancer and other cancer types.

References

1. Huang S, Yang Q, Zheng X, Chow KM, Wu J, Zhu J. Predictors of surgery choices in women with early-stage breast cancer in China: a retrospective study. Bmc Cancer 2023; 23(1): 23.
2. Li J, Chen C, Nie J, Wang L, Zhang Z, Li Y. Changes in the disease burden of breast cancer along with attributable risk factors in China from 1990 to 2019 and its projections: An analysis of the global burden of disease study 2019. Cancer Med-Us 2023; 12(2): 1888-902.
3. Yin M, Wang F, Zhang Y, Meng R, Yuan X, Wang Q, et al. Analysis on Incidence and Mortality Trends and Age-Period-Cohort of Breast Cancer in Chinese Women from 1990 to 2019. Int J Env Res Pub He 2023; 20(1): 826.
4. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Ca-Cancer J Clin 2023; 73(1): 17-48.
5. Sun Y, Ma Y, Cao M, Hu Z, Lin W, Chen M, et al. Breast and cervical cancer screening adherence in Jiangsu, China: An ecological perspective. Front Public Health 2022; 10: 967495.
6. Noruzinia M, Tavakkoly-Bazzaz J, Ahmadvand M, Azimi F, Dehghanifard A, Khakpour G. Young Breast Cancer: Novel Gene Methylation in WBC. Asian Pac J Cancer Prev 2021; 22(8): 2371-5.
7. Zhang W, Wang H, Qi Y, Li S, Geng C. Epigenetic study of early breast cancer (EBC) based on DNA methylation and gene integration analysis. Sci Rep-Uk 2022; 12(1): 1989.
8. Ekici S, Jawzal H. Breast cancer diagnosis using thermography and convolutional neural networks. Med Hypotheses 2020; 137: 109542.
9. Mammoottil MJ, Kulangara LJ, Cherian AS, Mohandas P, Hasikin K, Mahmud M. Detection of Breast Cancer from Five-View Thermal Images Using Convolutional Neural Networks. J Healthc Eng 2022; 2022: 4295221.
10. Kuhl CK. Abbreviated Magnetic Resonance Imaging (MRI) for Breast Cancer Screening: Rationale, Concept, and Transfer to Clinical Practice. Annu Rev Med 2019; 70: 501-19.
11. Gu WQ, Cai SM, Liu WD, Zhang Q, Shi Y, Du LJ. Combined molybdenum target X-ray and magnetic resonance imaging examinations improve breast cancer diagnostic efficacy. World J Clin Cases 2022; 10(2): 485-91.
12. Saadatmand S, Geuzinge HA, Rutgers E, Mann RM, de Roy VZD, Zonderland HM, et al. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial. Lancet Oncol 2019; 20(8): 1136-47.
13. Magbanua M, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol 2021; 32(2): 229-39.
14. Prat A, Braso-Maristany F, Martinez-Saez O, Sanfeliu E, Xia Y, Bellet M, et al. Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. Nat Commun 2023; 14(1): 1157.
15. Sant M, Bernat-Peguera A, Felip E, Margeli M. Role of ctDNA in Breast Cancer. Cancers 2022; 14(2): 310.
16. Moss J, Zick A, Grinshpun A, Carmon E, Maoz M, Ochana BL, et al. Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer. Ann Oncol 2020; 31(3): 395-403.
17. Chen M, Zhao H. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum Genomics 2019; 13(1): 34.
18. Alimirzaie S, Bagherzadeh M, Akbari MR. Liquid biopsy in breast cancer: A comprehensive review. Clin Genet 2019; 95(6): 643-60.
19. Karami FM, Azargoonjahromi A, Kiani A, Jalalifar F, Osati P, Akbari OM, et al. The role of epigenetic modifications in drug resistance and treatment of breast cancer. Cell Mol Biol Lett 2022; 27(1): 52.
20. Markou A, Tzanikou E, Lianidou E. The potential of liquid biopsy in the management of cancer patients. Semin Cancer Biol 2022; 84: 69-79.
21. Zhang J, Zhang F, Zhang F, Wu H, Zhang B, Wu X. Correlation between promoter methylation of the LDH-C4 gene and DNMT expression in breast cancer and their prognostic significance. Oncol Lett 2022; 23(1): 35.
22. Hu R, Zhou XJ, Li W. Computational Analysis of High-Dimensional DNA Methylation Data for Cancer Prognosis. J Comput Biol 2022; 29(8): 769-81.
23. Umeh-Garcia M, O'Geen H, Simion C, Gephart MH, Segal DJ, Sweeney CA. Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer. Brit J Cancer 2022; 127(3): 436-48.
24. Hai L, Li L, Liu Z, Tong Z, Sun Y. Whole-genome circulating tumor DNA methylation landscape reveals sensitive biomarkers of breast cancer. Medcomm 2022; 3(3): e134.
25. Xiong Z, Li X, Yang L, Wu L, Xie Y, Xu F, et al. Integrative Analysis of Gene Expression and DNA Methylation Depicting the Impact of Obesity on Breast Cancer. Front Cell Dev Biol 2022; 10: 818082.
26. Khan MI, Nur SM, Abdulaal WH. A study on DNA methylation modifying natural compounds identified EGCG for induction of IFI16 gene expression related to the innate immune response in cancer cells. Oncol Lett 2022; 24(1): 218.
27. Fu J, Zhang L, Li D, Tian T, Wang X, Sun H, et al. DNA Methylation of Imprinted Genes KCNQ1, KCNQ1OT1, and PHLDA2 in Peripheral Blood Is Associated with the Risk of Breast Cancer. Cancers 2022; 14(11): 2652.
28. Xu Z, Sandler DP, Taylor JA. Blood DNA Methylation and Breast Cancer: A Prospective Case-Cohort Analysis in the Sister Study. Jnci-J Natl Cancer I 2020; 112(1): 87-94.
29. Gohno T, Hanamura T, Kurosumi M, Takei H, Yamaguchi Y, Hayashi SI. One DNA Methylation Regulates CHIP Gene Expression of Human Breast Cancer and Predicts Recurrence. Anticancer Res 2022; 42(2): 759-66.
30. Li Q, Huang Z, Peng Y, Wang X, Jiang G, Wang T, et al. RanBP3 Regulates Proliferation, Apoptosis and Chemosensitivity of Chronic Myeloid Leukemia Cells via Mediating SMAD2/3 and ERK1/2 Nuclear Transport. Front Oncol 2021; 11: 698410.
31. Tang W, Zhu Y, Qin W, Zhang H, Zhang H, Lin H, et al. Ran-binding protein 3 is associated with human spermatogenesis and male infertility. Andrologia 2020; 52(2): e13446.
32. Serras AS, Camoes SP, Antunes B, Costa VM, Dionisio F, Yazar V, et al. The Secretome of Human Neonatal Mesenchymal Stem Cells Modulates Doxorubicin-Induced Cytotoxicity: Impact in Non-Tumor Cells. Int J Mol Sci 2021; 22(23): 13072.
33. Zhao X, Hu D, Li J, Zhao G, Tang W, Cheng H. Database Mining of Genes of Prognostic Value for the Prostate Adenocarcinoma Microenvironment Using the Cancer Gene Atlas. Biomed Res Int 2020; 2020: 5019793.
34. Visser J, van Geel M, Cornelissen A, van der Hulst R, Qiu SS. Breast Cancer-Related Lymphedema and Genetic Predisposition: A Systematic Review of the Literature. Lymphat Res Biol 2019; 17(3): 288-93.
35. Andreopoulos B, Anastassiou D. Integrated Analysis Reveals hsa-miR-142 as a Representative of a Lymphocyte-Specific Gene Expression and Methylation Signature. Cancer Inform 2012; 11: 61-75.
36. Zhang J, Wang L, Xu X, Li X, Guan W, Meng T, et al. Transcriptome-Based Network Analysis Unveils Eight Immune-Related Genes as Molecular Signatures in the Immunomodulatory Subtype of Triple-Negative Breast Cancer. Front Oncol 2020; 10: 1787.
37. Chang TW, Chen CC, Chen KY, Su JH, Chang JH, Chang MC. Ribosomal phosphoprotein P0 interacts with GCIP and overexpression of P0 is associated with cellular proliferation in breast and liver carcinoma cells. Oncogene 2008; 27(3): 332-8.
38. Geradts J, Groth J, Wu Y, Jin G. Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS). Breast Cancer Res Tr 2016; 157(3): 447-59.
39. Li L, Huang H, Zhu M, Wu J. Identification of Hub Genes and Pathways of Triple Negative Breast Cancer by Expression Profiles Analysis. Cancer Manag Res 2021; 13: 2095-104.
40. Lu B, Natarajan E, Balaji RH, Markandan UD. Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review. Technol Cancer Res T 2023; 22: 2081080162.
Published
2023/12/18
Issue
Ahead of print
Section
Original paper

Copyright (c) 2023 Qin Hu, Yu Mao, Haomiao Lan, Yi Wei, Yuehua Chen, Qiang Ye, Hongying Che

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.